DSIP

The speaker notes that DSIP has been studied as an aid for individuals coming off opioid medications and alcohol, citing this as evidence that it does not behave like a drug of abuse. This is presented as a distinguishing feature from addictive substances, though no specific study citations or sample sizes are provided. The speaker uses this to reassure viewers who may be concerned about the word 'opioid' in the mechanism description.

Dr. Tatem's overall stance is skeptical. He says DSIP should not be thought of like Ambien; it is not a sedative and nothing in the human record shows it dropping people in 20 minutes. He characterizes it as a slow nudge to the sleep system and body clock, a chronobiologic much like melatonin but not a knockout. Unlike CJC/Cortexin's 30-year Russian track record, DSIP lacks approval for the sleep indication people want. His verdict: adults with wrecked sleep should not reach for gray-market DSIP first but focus on sleep basics (consistent schedule, sunlight, no night screens, dark cold room, less alcohol, rule out apnea), and he says we honestly just need more data.

Dr. Tatem explains DSIP (government name emadeltide) was eligible for US compounding until the FDA moved it to category 2 in 2023. It is among 12 peptides the FDA is now reconsidering, with a PCAC advisory hearing on July 24 sharing the docket with CJC and Epitalon. He clarifies the PCAC vote is advisory only and DSIP remains in regulatory limbo, and that the uses under review (opioid withdrawal, chronic insomnia, narcolepsy) are exactly where old foreign literature is thickest but modern evidence thinnest.

Dr. Tatem says the honest answer on danger is that no evidence of harm has been seen but we mostly do not know, and not knowing is itself a risk. Old IV studies reported DSIP was well tolerated with slow injection, with a few headaches but no major problems. He calls regulator-raised concerns about immune reactions to compounded DSIP purely theoretical. The Russian Deltaran label lists pregnancy, breastfeeding, and age under 18 as contraindications, with caution for very slow heart rate.

Dr. Tatem describes a mismatch between research and real-world use. Every controlled human study used slow IV administration at about 21 micrograms per kilo (roughly 1.5 mg for a 70 kg adult), with the slow push described as essential. The gray market instead uses a fraction of that dose subcutaneously or intranasally at home, extrapolating from Russian Deltaran dosing and marginal IV studies. He states this is descriptive, not a how-to or endorsement.

Dr. Tatem stresses that despite 50 years of study, no one has identified the gene that makes DSIP, the precursor protein it is cut from, or a specific receptor it binds. He frames this as DSIP being in 'limbo,' noting we built a sleep drug, named it after brain waves, and injected it into humans without even proving the body makes it naturally. He concedes it is definitely a peptide but says whether it is natural is unknown.

Dr. Tatem recounts that DSIP originated with Marcel Monnier and Guido Schoenenberger in Basel, Switzerland in the 1960s. They electrically stimulated a sleep-related thalamic region in a rabbit, collected blood from the sleeping rabbit's brain, and injected it into an awake rabbit, which became sleepy. Over about a decade they isolated, sequenced, and synthesized the responsible peptide, publishing it in 1977 and naming it after the delta waves of deep sleep it was supposed to produce.

Dr. Tatem describes DSIP (delta sleep-inducing peptide) as a nonapeptide, nine amino acids in a line (tryptophan, alanine, glycine, glycine, aspartic acid, alanine, serine, glycine, glutamate), weighing about 849 daltons. He notes its official FDA drug name is emadeltide. He places it between KPV (342) and BPC-157 (1419) on the size scale, calling it a small, simple, easy-to-synthesize molecule that is nonetheless biologically hard to understand.

The speaker distinguishes between DSIP sourced from a licensed 503A compounding pharmacy versus research-grade vials from overseas suppliers labeled 'not for human consumption.' The speaker explicitly recommends only pharmaceutical-grade sourcing and warns against the research vial route. This is framed as a safety and quality concern relevant to anyone considering DSIP use.

The speaker flags that DSIP's compatibility with other medications has not been fully established and that individuals on other medications should seek qualified medical guidance before using it. The speaker explicitly states that questions about drug interactions are among the key judgment calls that determine whether DSIP works safely or causes problems. This is presented as a reason to seek medical oversight rather than self-administer.

Notably, the speaker does not provide any specific dosage information for DSIP throughout the entire video, including no mention of micrograms, milligrams, injection frequency, or timing relative to sleep. The speaker instead directs viewers to book a consultation with their medical team for individualized protocol guidance. This is a relevant absence for anyone seeking practical dosing information from this source.

The speaker emphasizes that DSIP is not a substitute for addressing the underlying causes of poor sleep, such as chronic stress, poor scheduling, alcohol use, excessive screen time, or metabolic dysfunction. DSIP is positioned as a tool to restore deep sleep long enough to create a window during which the user can fix the root causes. Failure to use this window is described as the key reason people get stuck on the peptide.

The speaker strongly recommends using DSIP as a short-term intervention, on the order of a couple of weeks to one to two months maximum. This recommendation is driven by the absence of long-term safety data rather than a known harm signal. The intended use case is acute periods of sleep disruption such as high stress, illness, surgery recovery, or loss, after which the user should wean off.

The speaker argues that fixing deep sleep with DSIP indirectly enhances the effectiveness of all other peptides and therapies in a protocol. Deep sleep is described as the 'master amplifier' for recovery, fat loss, focus, and other outcomes. By restoring the deep sleep foundation, DSIP is claimed to lift the performance of an entire peptide stack.

The speaker explicitly states that DSIP and growth hormone peptides are not mutually exclusive and can be stacked together. GH peptides work the growth hormone rhythm while DSIP works sleep architecture directly, meaning they address the same problem from different angles. This stacking approach is recommended for individuals already on a GH peptide whose deep sleep remains impaired.

The speaker differentiates DSIP from growth hormone-releasing peptides such as Sermorelin, CJC-1295, Ipamorelin, and Tesamorelin. GH peptides primarily target the growth hormone axis, with improved sleep as a secondary benefit, whereas DSIP directly targets sleep architecture and the delta state. The speaker recommends DSIP when deep sleep is the primary problem, and GH peptides when growth hormone optimization is the primary goal with sleep as a bonus.

Beyond sleep, DSIP is described as interacting with the stress hormone axis, including cortisol regulation and the fight-or-flight response. Users reportedly experience reduced daytime tension and a calmer baseline in addition to improved sleep. The speaker frames sleep and stress as a bidirectional loop, with DSIP breaking that loop from both sides simultaneously.

DSIP is described as modulating neurotransmitters — brain chemicals that signal the nervous system to wind down or stay alert. It also appears to interact with the body's endogenous opioid peptide system, which is involved in calming and stress-signal reduction. The speaker acknowledges that the exact receptor targets have not been fully mapped by researchers, and explicitly states DSIP is not an opioid drug.

DSIP (Delta Sleep-Inducing Peptide) is described as working directly on sleep architecture, specifically nudging the brain toward delta wave states associated with slow-wave (deep) sleep. Unlike sedative sleep aids that simply induce unconsciousness, DSIP is claimed to deepen sleep quality by working with the brain's own machinery. The speaker emphasizes this distinction: sedation is not the same as improving deep sleep.

The speaker frames DSIP use as potentially symptomatic rather than curative, arguing that peptide intervention without addressing lifestyle factors is insufficient. Specific lifestyle variables cited include diet, exercise habits, screen time, and nighttime routine. This constitutes a safety-adjacent warning against over-reliance on peptides for sleep without foundational behavioral changes. No clinical evidence or studies are cited to support this position.

The speaker suggests DSIP (referred to as 'DCIP' in the transcript, likely a mispronunciation) may be considered for sleep issues, but emphasizes it should not be treated as a primary solution. The speaker's core position is that underlying causes of poor sleep — diet, exercise, screen time, nighttime routine, and stress management — must be addressed first. No dosage, frequency, or administration route is mentioned.

The speaker outlines a structured three-domain framework for peptide use in perimenopausal women: (1) metabolic system — tirzepatide or retatrutide for weight and appetite control; (2) sleep quality — selank or DSIP for anxiety and sleep; (3) growth hormone axis — tesamorelin or CJC-1295 for GH support. This represents the only explicit stacking/protocol structure in the video. No dosages, frequencies, or cycling protocols are provided for any of the three domains.

The speaker makes a broad protocol-level finding that all peptide interventions in perimenopause are symptomatic management tools and should only be introduced as a 'second layer' after the underlying hormonal deficiency (progesterone first, then estrogen) has been addressed. Using peptides without correcting the progesterone-estrogen ratio is characterized as insufficient. This represents a stacking and sequencing recommendation applicable to all peptides discussed in the video.

DSIP is mentioned alongside Selank as a peptide option to improve sleep quality in perimenopausal women. The speaker does not differentiate the mechanisms of Selank versus DSIP in this context, grouping them together as sleep and anxiety support tools. No dosage, frequency, or route of administration is provided. It is framed as symptomatic management only.

The speaker acknowledges that some users experience lasting sleep improvement after a short DSIP course even without making lifestyle changes, suggesting the peptide may help reset the body's sleep rhythm in a durable way for certain individuals. However, the speaker cautions against relying on this outcome and recommends using the treatment window to address root causes. This is presented as a real but unpredictable possibility.

The speaker shares a patient case in which an individual who had experienced nearly a year of poor sleep, tracked via a wearable device, saw measurable increases in deep sleep within just two nights of starting DSIP. No dosage details are provided. The speaker uses this case to illustrate both the rapid efficacy of DSIP and the reason why users are tempted to remain on it long-term.

The speaker warns that extended use of DSIP can lead to a dependency pattern where users cannot sleep without it, experiencing rebound insomnia upon missing a dose. This is described as a common mistake observed in patients who feel the initial benefit and choose to remain on DSIP indefinitely. The speaker frames this as a behavioral/protocol trap rather than a pharmacological addiction, but cautions it is a real risk.

Dr. Tatem points out the one real regulated DSIP product is Deltaran in Russia, a nasal spray dosed at 0.3 mg per ampule, officially approved for alcohol withdrawal and stress states but not insomnia. He finds it notable that the only place DSIP is an approved medicine, it is not approved for sleep.

Dr. Tatem notes that outside of sleep the evidence gets even thinner: a few open uncontrolled series from the 1980s and an open opioid-detox trial in the 1990s looked at DSIP for alcohol and opioid withdrawal with no real control group, plus a pilot study in seven people for chronic pain and a single case report in one narcolepsy patient.

Dr. Tatem states the human data is small, old, mostly from the 1980s, and mixed. Early open-label IV studies by the Swiss discoverers reported insomniacs' sleep normalizing, but a 1987 crossover study found improvement of little clinical significance, and the most rigorous trial, a 1992 double-blind study of 16 chronic insomniacs, found only weak effects with no subjective improvement and authors concluding short-term DSIP was 'not likely to be a major therapeutic benefit.'

Dr. Tatem summarizes broad animal data: rabbits get more slow delta and spindle waves, cats get more REM (dreaming) sleep rather than deep sleep, and rats show more slow-wave sleep and a bump in growth hormone. He cites a 2021 rat study where intranasal DSIP before an induced stroke did not significantly shrink stroke damage but did improve motor recovery on a rotating treadmill. He emphasizes every bit of this is in animals.

Dr. Tatem notes DSIP is shredded by enzymes and gone from the bloodstream in about 2 to 4 minutes, yet old human reports describe effects taking about an hour to begin and then lingering up to 20 hours. He acknowledges the mismatch but compares it to growth hormone, whose short half-life produces longer effects via IGF-1 (half-life ~15 hours).

Dr. Tatem highlights that DSIP breaks the usual dose-response pattern. Instead of more dose producing more effect up to a plateau, a little does a lot but more does less, meaning it can be overshot. He warns this U-shaped curve makes dosing a minefield and means the 'just double it' instinct does not work and may make things worse.

Dr. Tatem lists the leads researchers have on DSIP without a confirmed mechanism. It nudges a pineal-gland enzyme through an adrenergic pathway (a circadian-clock fingerprint shown in rats); it triggers release of the endogenous opioid met-enkephalin in brainstem tissue, with naloxone blunting animal responses; and it appears to modulate the excitatory NMDA and calming GABA systems, mostly in rat stroke and seizure models. He repeatedly notes these findings are in rats.